Reference List



BR.10 – Stefan Michiels

Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (Abstract 7004)

Oral Abstract Session – Lung Cancer – Local Regional and Adjuvant Therapy/Small Cell

Tuesday: 8:00 AM – 11:00 AM, Location: Arie Crown Theatre

Presentation Time: 9:45 AM – 10:00 AM

Chair and/or Co-chairs: Tom Stinchcombe, MD & Wilfried E. Eberhardt, MD

BR.21 – John F. Hilton

An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib.

Poster Discussion Session –Lung Cancer – Metastatic/Non-small Cell

Monday: 2:00 PM - 6:00 PM (Location: E450a)

Discussion: Monday: 5:00 PM 6:00 PM (Location: Hall D2)

Board No. 12 Abstract No. 7523

CO.17 – Elena Elimova

Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial.

General Poster Session – Gastrointestinal (Colorectal) Cancer

Saturday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 20H Abstract No. 3624

CO.17 – Christopher J. O’Callaghan

The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.

General Poster Session – Gastrointestinal (Colorectal) Cancer

Saturday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 16D Abstract No. 3588

CO.17 – Guy A. Van Hazel

Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study.

General Poster Session – Gastrointestinal (Colorectal) Cancer

Saturday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 18B Abstract No. 3602

CO.17 – Michael M. Vickers

The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG / AGITG CO.17.

General Poster Session – Gastrointestinal (Colorectal) Cancer

Saturday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 18A Abstract No. 3601

CO.20 – Jeremy D. Shapiro

A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.

Trials in Progress Poster Session

Monday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 44A Abstract No. TPS163

IND.192 – Helen Mackay

Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.

Poster Discussion Session –Gynecologic Cancer

Friday: 2:00 PM - 6:00 PM (Location: E450a)

Discussion: Friday: 5:00 PM 6:00 PM (Location: E354b)

Board No. 2 Abstract No. 5013

LY.11 – Patrick J. Stiff

Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP±R for eight cycles to CHOP±R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin's lymphoma (NHL). (Abstract 8001)

Oral Abstract Session – Lymphoma

Saturday: 1:30 PM – 4:00 PM, Location: S406

Presentation Time: 1:45 PM – 2:00 PM

Chair and/or Co-chairs: Myron S. Czuczman, MD & Gilles A. Salles, MD, PhD

MA.5 – Maggie Chon U. Cheang

The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.

Poster Discussion Session – Breast Cancer – Triple-negative/Cytotoxics/ Local Therapy

Saturday: 2:00 PM – 6:00 PM (Location: E450b)

Discussion: Saturday; 5:00 PM to 6:00 PM (Location: Hall B1)

Board No. 22 Abstract No. 1032

Dr. Cheang’s abstract was selected for the Novartis Oncology Young Canadian Investigator Awards (NOYCIA). Presentations will be made at a dinner on Sunday June 5th, at 6:30 pm at the Trump International Hotel.

MA.12 – Mark Basik

Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer.

General Poster Session – Breast Cancer – HER2/ER

Monday: 1:00 PM – 5:00 PM (Location: Hall A)

Board No. 4B Abstract No. 560

MA.12-MA.14-MA.21-MA.27-MA.5 – Rinat Yerushalmi

Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer.

Poster Discussion Session – Breast Cancer – HER2/ER

Tuesday: 8:00 AM – 12:00 PM (Location: E450a)

Discussion: Tuesday; 11:30 AM to 12:30 PM (Location: Arie Crown Theater)

Board No. 2 Abstract No. 513

MA.14 – Adriana Aguilar-Mahecha

Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.

General Poster Session – Breast Cancer – HER2/ER

Monday: 1:00 PM – 5:00 PM (Location: Hall A)

Board No. 6C Abstract No. 577

MA.20 – Timothy J. Whelan

Highlighted in ASCO Official Press Program and selected for Best of ASCO

NCIC-CTG MA.20: An Intergroup Trial of Regional Nodal Irradiation in Early Breast Cancer

(Abstract LBA1003)

Oral Abstract Session – Breast Cancer –Triple-negative/Cytotoxics/Local Therapy

Monday: 9:30 AM – 12:30 PM, Location: Hall B1

Presentation Time: 9:45 AM – 10:00 AM

Chair and/or Co-chairs: Lisa Yee, MD, and Melinda L. Telli, MD

MA.27B – Dawn L. Hershman

Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study.

Poster Discussion Session – Breast Cancer – HER2/ER

Tuesday: 8:00 AM – 12:00 PM (Location: E450a)

Discussion: Tuesday; 11:30 AM to 12:30 PM (Location: Arie Crown Theater)

Board No. 7 Abstract No. 518

MA.27 – Vered Stearns

Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial.

Poster Discussion Session – Breast Cancer – HER2/ER

Tuesday: 8:00 AM – 12:00 PM (Location: E450a)

Discussion: Tuesday: 11:30 AM to 12:30 PM (Location: Arie Crown Theater)

Board No. 14 Abstract No. 525

MA.31 – Wendy Parulekar

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919).

Trials in Progress Poster Session

Monday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 37B Abstract No. TPS108

MA.32 – Wendy Parulekar

A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).

Trials in Progress Poster Session

Monday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 36E Abstract No. TPS103

MAP.3 – Paul E. Goss

Highlighted in ASCO Official Press Program and selected for Best of ASCO

Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 - A randomized placebo-controlled clinical trial. (Abstract LBA504)

Oral Abstract Session – Breast Cancer – HER2/ER

Sunday: 9:00 AM – 12:00 PM, Location: Hall B1

Presentation Time: 9:00 AM – 9:15 AM

Chair and/or Co-chairs: Harold J. Burstein, MD, PhD & Rebecca A. Dent, MD, FRCPC

OV.15 – Christian Kurzeder

The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5.

General Poster Session – Gynecologic Cancer

Sunday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 20D Abstract No. 5088

OV.17 – Sven Mahner

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.

General Poster Session – Gynecologic Cancer

Sunday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 16G Abstract No. 5059

OV.17 – Christian Marth

Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.

General Poster Session – Gynecologic Cancer

Sunday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 15H Abstract No. 5052

OV.17 – Benoit You

Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study.

General Poster Session – Gynecologic Cancer

Sunday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 17E Abstract No. 5065

OV.19 – Gunnar Kristensen

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. (Abstract LBA5006)

Oral Abstract Session – Gynecologic Cancer

Saturday: 3:00 PM – 6:00 PM, Location: E354a

Presentation Time: 4:00 PM – 4:15 PM

Chair and/or Co-chairs: Ronald J. Buckanovich, MD & Gottfried E. Konecny, MD

PR.7 – Juanita M. Crook - Selected for Best of ASCO

A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/ 01/013). (Abstract 4514)

Oral Abstract Session – Genitourinary Cancer (Prostate)

Monday: 1:00 PM – 4:00 PM, Location: Hall D1

Presentation Time: 2:30 PM – 2:45 PM

Chair and/or Co-chairs: Joshi J. Alumkal, MD, and Ajjai S. Alva, MBBS, MS

Other – Judy-Anne W. Chapman

Comparison of innovative estimation of efficacy to standard using the ACCENT database.

General Poster Session – Gastrointestinal (Colorectal) Cancer

Saturday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 19H Abstract No. 3616

Other – Melanie Walker

Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study.

General Poster Session – Health Services Research

Saturday: 8:00 AM – 12:00 PM (Location: Hall A)

Board No. 51G Abstract No. 6131

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download